Revvity has launched the SuperFlex prenatal screening system, a CE-IVDR certified immunoassay instrument for small and mid-sized labs, supporting preeclampsia and biochemical screening in low-volume workflows, the company announced.
The funding will support the expansion of the Syn-One Test, a skin biopsy-based laboratory developed test for neurodegenerative diseases.
As Cyclospora infections surge in the US, laboratories face increased pressure to quickly differentiate cases, with the CDC reporting 1,947 confirmed infections and 98 hospitalizations across nine states as of July 24.
A Cedars-Sinai study in JAMA Network Open reports women testing negative for BRCA mutations but with a family cancer history face a 25% lifetime breast cancer risk, underscoring the importance of family history in risk assessment.
A Quest Diagnostics study of 1.5 million women found those with bacterial vaginosis are over three times more likely to have a non-viral STI, highlighting the need for comprehensive diagnostic testing.
HerAnova Lifesciences reported real-world data on its HerResolve multi-omic blood test for endometriosis at the 2026 Midwest Reproductive Annual Symposium, showing consistent performance across 197 cases in diverse clinical settings.
A new ultrasensitive blood test may detect Sjögren’s disease more than 10 years before symptoms appear by identifying chronically elevated interferon alpha levels in patient blood samples.
Labcorp has announced the upcoming launch of the Marker by Labcorp Genetic Health Panel, which will analyze 163 genes linked to over 100 medically actionable conditions, with results supported by licensed genetic counselors.
Imperial College London has begun integrating C2N’s PrecivityAD2 blood test into primary care pathways for Alzheimer’s diagnosis, as part of the BEAD-PC study and the Davos Alzheimer’s Collaborative initiative.
Research presented at ADLM 2026 indicates immunoassays may significantly underestimate HbA1c in patients with sickle cell trait, suggesting HPLC offers more reliable diabetes screening for populations with hemoglobin variants.
Elevated donor-derived cell-free DNA levels are linked to higher kidney transplant failure risk, suggesting earlier detection of allograft injury before loss of kidney function.
The Cystic Fibrosis Base assay has received IVDR accreditation, ensuring high standards for detecting cystic fibrosis mutations.
The BD BACTEC FXI Culture System reduces detection time for bloodstream infections by approximately three hours compared to previous models.